Home > Medicine & Health Science textbooks > Surgery > Gremlin2 Promotes the Enrichment of Cd44 Cancer Stem Cells After Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: (English)
Gremlin2 Promotes the Enrichment of Cd44 Cancer Stem Cells After Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: (English)

Gremlin2 Promotes the Enrichment of Cd44 Cancer Stem Cells After Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: (English)

          
5
4
3
2
1

Out of Stock


Premium quality
Premium quality
Bookswagon upholds the quality by delivering untarnished books. Quality, services and satisfaction are everything for us!
Easy Return
Easy return
Not satisfied with this product! Keep it in original condition and packaging to avail easy return policy.
Certified product
Certified product
First impression is the last impression! Address the book’s certification page, ISBN, publisher’s name, copyright page and print quality.
Secure Checkout
Secure checkout
Security at its finest! Login, browse, purchase and pay, every step is safe and secured.
Money back guarantee
Money-back guarantee:
It’s all about customers! For any kind of bad experience with the product, get your actual amount back after returning the product.
On time delivery
On-time delivery
At your doorstep on time! Get this book delivered without any delay.
Notify me when this book is in stock
Add to Wishlist
X

About the Book

This dissertation, "Gremlin2 Promotes the Enrichment of CD44 Cancer Stem Cells After Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma" by Hoi-tung, Kwan, 關愷彤, was obtained from The University of Hong Kong (Pokfulam, Hong Kong) and is being sold pursuant to Creative Commons: Attribution 3.0 Hong Kong License. The content of this dissertation has not been altered in any way. We have altered the formatting in order to facilitate the ease of printing and reading of the dissertation. All rights not granted by the above license are retained by the author. Abstract: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. While HCC patients at early stages are eligible for liver resection and liver transplantation, patients diagnosed at late stages can only be treated with palliative therapies. Transarterial chemoembolization (TACE) is the standard treatment for un-resectable HCC, involving the induction of tumor ischemia and chemotherapy. It aims to reduce tumor growth and improve patient survival. However, the tumor response rate of TACE is often unsatisfactory. Recently, the rise of the 'cancer stem cell' model has opened a new field for cancer research. This novel theory postulates that only a small fraction of cells can initiate tumor and they are named cancer stem cells (CSCs). They are characterized with the abilities in tumor initiation, chemoresistance and enhanced stem cell properties. It is suggested that they are attributed to the resistance of standard chemotherapies. Therefore, exploring effective treatment strategies to specifically target and eliminate CSCs will be the key to tackling HCC. To investigate the underlying mechanisms by which HCC resists TACE, in vivo TACE was performed in the mouse model with orthotopic HCC. Herein, the enrichment of CD44+ hepatic CSCs was observed in TACE-treated HCC tumors in vivo. Moreover, CD44+ HCC cells possessed enhanced tumor-initiating capacity and increased ability in spheroid formation. These results suggested that CD44+ HCC cells are a potential population of CSCs. We also examined the possible mechanism by which TACE leads to the enrichment of CD44+ CSCs. The gene expression profile of TACE treated tumors in comparison to that of untreated tumors was examined by RNA sequencing. Among all of the differentially expressed genes, Gremlin2, which is a secreted BMP antagonist, was found to be up-regulated in all treatment groups and the most significant increase iGremlin2 expression was observed in TACE-treated samples. Furthermore, the oncogenic roles of Gremlin2 were studied. Exogenous application of human recombinant Gremlin2 resulted in the enrichment of CD44+ CSCs and increased the expression of several stemness genes including SOX2, OLIGO2, NANOG and OCT4 in HCC cell lines. In addition, treatment with Gremlin2 reduced the activation of both endogenous and BMP ligands-induced Smad1/5 signalling in a dose-dependent and time-dependent manner. Besides, Gremlin2-overexpressing HCC cells showed CSC phenotypes along with enhanced tumorigenic potential characterized by increased abilities in cell growth, cell migration and invasion. Moreover, Gremlin2 but no other BMP antagonists, ligands or receptors was preferentially expressed in CD44+ CSCs with compromised BMP signalling. More importantly, Gremlin2 could antagonize the BMP ligands-induced Smad1/5 activation in CD44+ CSCs. Taken together, these findings suggested that Gremlin2 controls the maintenance of CSCs by suppressing BMP signalling. In conclusion, this study demonstrated that the upregulation of Gremlin2 resulted from TACE may contribute to the enrichment of CSCs through attenuation of BMP signalling, which consequently promotes the growth of HCC tumors. These findings revealed a novel therapeutic target for eradicating CSCs in the treatment of HCC. Subjects: Stem cells Liver - Cancer - Treatment Cancer cell


Best Sellers


Product Details
  • ISBN-13: 9781361029718
  • Publisher: Open Dissertation Press
  • Publisher Imprint: Open Dissertation Press
  • Height: 279 mm
  • No of Pages: 162
  • Spine Width: 11 mm
  • Width: 216 mm
  • ISBN-10: 1361029714
  • Publisher Date: 26 Jan 2017
  • Binding: Hardback
  • Language: English
  • Series Title: English
  • Weight: 671 gr


Similar Products

How would you rate your experience shopping for books on Bookswagon?

Add Photo
Add Photo

Customer Reviews

REVIEWS           
Click Here To Be The First to Review this Product
Gremlin2 Promotes the Enrichment of Cd44 Cancer Stem Cells After Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: (English)
Open Dissertation Press -
Gremlin2 Promotes the Enrichment of Cd44 Cancer Stem Cells After Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: (English)
Writing guidlines
We want to publish your review, so please:
  • keep your review on the product. Review's that defame author's character will be rejected.
  • Keep your review focused on the product.
  • Avoid writing about customer service. contact us instead if you have issue requiring immediate attention.
  • Refrain from mentioning competitors or the specific price you paid for the product.
  • Do not include any personally identifiable information, such as full names.

Gremlin2 Promotes the Enrichment of Cd44 Cancer Stem Cells After Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: (English)

Required fields are marked with *

Review Title*
Review
    Add Photo Add up to 6 photos
    Would you recommend this product to a friend?
    Tag this Book
    Read more
    Does your review contain spoilers?
    What type of reader best describes you?
    I agree to the terms & conditions
    You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.

    CUSTOMER RATINGS AND REVIEWS AND QUESTIONS AND ANSWERS TERMS OF USE

    These Terms of Use govern your conduct associated with the Customer Ratings and Reviews and/or Questions and Answers service offered by Bookswagon (the "CRR Service").


    By submitting any content to Bookswagon, you guarantee that:
    • You are the sole author and owner of the intellectual property rights in the content;
    • All "moral rights" that you may have in such content have been voluntarily waived by you;
    • All content that you post is accurate;
    • You are at least 13 years old;
    • Use of the content you supply does not violate these Terms of Use and will not cause injury to any person or entity.
    You further agree that you may not submit any content:
    • That is known by you to be false, inaccurate or misleading;
    • That infringes any third party's copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy;
    • That violates any law, statute, ordinance or regulation (including, but not limited to, those governing, consumer protection, unfair competition, anti-discrimination or false advertising);
    • That is, or may reasonably be considered to be, defamatory, libelous, hateful, racially or religiously biased or offensive, unlawfully threatening or unlawfully harassing to any individual, partnership or corporation;
    • For which you were compensated or granted any consideration by any unapproved third party;
    • That includes any information that references other websites, addresses, email addresses, contact information or phone numbers;
    • That contains any computer viruses, worms or other potentially damaging computer programs or files.
    You agree to indemnify and hold Bookswagon (and its officers, directors, agents, subsidiaries, joint ventures, employees and third-party service providers, including but not limited to Bazaarvoice, Inc.), harmless from all claims, demands, and damages (actual and consequential) of every kind and nature, known and unknown including reasonable attorneys' fees, arising out of a breach of your representations and warranties set forth above, or your violation of any law or the rights of a third party.


    For any content that you submit, you grant Bookswagon a perpetual, irrevocable, royalty-free, transferable right and license to use, copy, modify, delete in its entirety, adapt, publish, translate, create derivative works from and/or sell, transfer, and/or distribute such content and/or incorporate such content into any form, medium or technology throughout the world without compensation to you. Additionally,  Bookswagon may transfer or share any personal information that you submit with its third-party service providers, including but not limited to Bazaarvoice, Inc. in accordance with  Privacy Policy


    All content that you submit may be used at Bookswagon's sole discretion. Bookswagon reserves the right to change, condense, withhold publication, remove or delete any content on Bookswagon's website that Bookswagon deems, in its sole discretion, to violate the content guidelines or any other provision of these Terms of Use.  Bookswagon does not guarantee that you will have any recourse through Bookswagon to edit or delete any content you have submitted. Ratings and written comments are generally posted within two to four business days. However, Bookswagon reserves the right to remove or to refuse to post any submission to the extent authorized by law. You acknowledge that you, not Bookswagon, are responsible for the contents of your submission. None of the content that you submit shall be subject to any obligation of confidence on the part of Bookswagon, its agents, subsidiaries, affiliates, partners or third party service providers (including but not limited to Bazaarvoice, Inc.)and their respective directors, officers and employees.

    Accept

    New Arrivals


    Inspired by your browsing history


    Your review has been submitted!

    You've already reviewed this product!
    ASK VIDYA